This week's reporting on compounded GLP-1 products raises a question that goes beyond weight-loss injections: how do you know a compounded peptide is chemically what it claims to be? Stanford Medicine clinicians and independent lab analyses are documenting real gaps — unapproved salt forms, undisclosed additives, and even newly formed molecules that don't exist in the approved drug. Here's what the research actually found, and why verified sourcing is the real answer.
Hidden Additives and Why Verified Testing Matters
The chemistry problem doesn't stop at the active ingredient. Many compounders add extra ingredients, most commonly vitamin B12, to differentiate their product from FDA-approved versions — additives with no proven weight-loss benefit and largely untested combinations. A 2026 lab analysis published in Expert Opinion on Drug Safety found that combining tirzepatide with B12 can form an entirely new, previously uncharacterized molecule that doesn't exist in the approved drug; researchers say its effects on the body remain unknown. A separate academic review found nearly half of compounded products tested contained additives like cyanocobalamin, glycine, or niacinamide with little scientific justification. Layer in the FDA's documented dosing errors from multidose vials, where patients have measured out ten to twenty times the intended dose, and the picture becomes clear: without independent verification, there's no reliable way to know what you're actually getting. That's the exact gap third-party lab testing and batch-specific certificates of analysis are built to close — verifying identity, purity, and concentration before a product ever reaches a researcher's bench.
The Vial May Not Match the Label
New reporting this week puts a blunt question in front of anyone using a compounded GLP-1 product: is what's actually in the vial the same drug that went through clinical trials? Often, it isn't. FDA-approved semaglutide and tirzepatide have a precise molecular structure carried through years of testing. Many compounding pharmacies instead use chemically distinct salt forms, such as semaglutide sodium, that have never been studied in humans and are not FDA-approved. Stanford Medicine's Dr. Marina Basina notes that effectiveness "can be different" with these substitutions. Formulation swaps add another layer of risk — sublingual drops and dissolving tablets are being marketed even though no clinical trial has ever evaluated them in that form.
